Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
Abacavir therapy is associated with significant drug hypersensitivity in approximately 8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allele. In this prospective study, involving 260 abacavir-naive individuals (7.7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701-negative recipients.
Rauch
A
A
Centre for Clinical Immunology and Biomedical Statistics, Perth, Australia. S.Mallal@murdoch.edu.au.
Nolan
D
D
Martin
A
A
McKinnon
E
E
Almeida
C
C
Mallal
Simon
S
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D001315:Australia; D015331:Cohort Studies; D015224:Dideoxynucleosides / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000453:epidemiology / Q000235:genetics* / Q000517:prevention & control; D005260:Female; D005820:Genetic Testing; D015658:HIV Infections / Q000188:drug therapy*; D015235:HLA-B Antigens / Q000235:genetics*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D015235:HLA-B Antigens; D000099227:Abacavir; C484830:HLA-B*57:01 antigen